JPRN-UMIN000015723已完成1 期
Phase 1 study of Docetaxel and Oxaliplatin and TS-1 for unresectable / recurrent gastric cancer (KOGC-06) - KOGC-06
Keio University School of Medicine, Department of Surgery0 个研究点目标入组 5 人开始时间: 2014年11月19日最近更新:
适应症
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 发起方
- 入组人数
- 5
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- 20years-old 至 75years-old（—）
- 性别
- All
入选标准
- 未提供
排除标准
- •(1) Patients with severe ischemic heart disease or arhythmia. (2) Patients with myocardial infarction within 6 months. (3) Patients with liver cirrhosis or active hepatitis. (4) Patients with dyspnea needing oxygen. (5) Patients with fresh gastrointestinal bleeding which require a repeat blood transfusion. (6) Patient who have been treated with antipsychotic drugs, or patient with mental disorder requiring medication. (7) Patients with uncontrolled diabetes mellitus. (8) Patients with ileus or subilues. (9) Patients with fever infection. (10) Patients who have history of active simultaneous or metachronous double cancers within 5 year. However, patient with carcinoma in situ or intramucosal carcinoma curable with local therapy is excluded for active double cancer. (11) Patients with CNS metastases. (12) Patients with acute infectious diseases. (13) Patients with peripheral neuropathy. (14) Patients with history of severe adverse event suspected to be caused by drugs. (15) Patients with history of severe adverse event suspected to be caused by Polyoxyethylene Castor Oil or hydroxyohlorinatedcasteroil. (16) Patients who are pregnant women, possibly pregnant women, willing to become pregnant, and nursing mothers. (17) Patients who are inappropriate for the study at the physician's assessment.
研究者
相似试验
进行中（未招募）
不适用
Phase II Study of Docetaxel, Oxaliplatin, Capecitabine with Bevacizumab and Trastuzumab in case of human epidermal growth factor receptor 2 (HER2)-positivity inPatients with Locally Advanced or Metastatic Gastric Cancer or Adenocarcinoma of the Gastro-oesophageal Junction (B-DOCT study) - B-DOCT studyocally Advanced or Metastatic Gastric Cancer or Adenocarcinoma of the Gastro-oesophageal JunctionMedDRA version: 12.1Level: PTClassification code 10063916Term: Metastatic gastric cancerMedDRA version: 12.1Level: LLTClassification code 10017758Term: Gastric cancerMedDRA version: 12.1Level: LLTClassification code 10066896Term: HER-2 positive gastric cancerEUCTR2010-022699-30-NLederlands Kanker Instutuut-Antonie van Leeuwenhoek Ziekenhuis
已完成
2 期
Phase II Study of Docetaxel, Oxaliplatin, Capecitabine with Bevacizumab and Trastuzumab in case of human epidermal growth factor receptor 2 (HER2)-positivity in Patients with Locally Advanced or Metastatic Gastric Cancer or Adenocarcinoma of the Gastro-oesophageal Junction (B-DOCT study)locally advanced or metastatic gastric cancer or adenocarcinoma of the gastro-oesophageal junctionmetastatic gastric cancer10017990NL-OMON39414Antoni van Leeuwenhoek Ziekenhuis90
招募中
1 期
DOS studygastric cancerJPRN-jRCTs061180095Takayama Tetsuji30
招募中
不适用
Phase I/II study of S-1, docetaxel, oxaliplatin combination chemotherapy (DOS) in patients with HER2-negative unresectable metastatic gastric cancergastric cancerJPRN-UMIN000015849Department of Gastroenterology and Oncology59
进行中（未招募）
不适用
Phase II study: Treatment with the drug docetaxel and oxaliplatin for patients who have a confirmed metastatic or locally advanced cancer of the pancreas and in whom initial therapy has failed.EUCTR2005-004236-40-DEniversitätsklinikum Ulm44